A class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors may be associated with rhabdomyolysis, a side effect which involves severe muscle damage.
In more detail, rhabdomyolysis is the breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood. These substances are harmful to the kidney and often cause kidney damage.
According to a new FDA quarterly report, “Potential Signals of Serious Risks / New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): April – June 2017”, the following 13 oral diabetes medicines are being investigated for this possible rhabdomyolysis side effect:
- Glyxambi (empagliflozin and linagliptin) tablets
- Janumet (sitagliptin and metformin hydrochloride) tablets
- Janumet XR (sitagliptin and metformin hydrochloride extended-release) tablets
- Januvia (sitagliptin) tablets
- Jentadueto (linagliptin and metformin hydrochloride) tablets
- Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets
- Kazano (alogliptin and metformin hydrochloride) tablets
- Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) tablets
- Nesina (alogliptin) tablets
- Onglyza (saxagliptin) tablets
- Oseni (alogliptin and pioglitazone) tablets
- Qtern (dapagliflozin and saxagliptin) tablets
- Tradjenta (linagliptin) tablets
We will be watching for reports of rhabdomyolysis in patients using Onglyza, Nesina, Januvia, and the other Type-2 diabetes drugs containing saxagliptin, alogliptin, sitagliptin, or linagliptin.
[View article at original source]